Becker & Poliakoff assisted Shenzhen Qianzhi BioTech Company Limited (“Qianzhi BioTech”), a Cayman Islands exempted company, in the negotiation, structuring, and documentation of a definitive Business Combination Agreement for a business combination with Bowen Acquisition Corp. (NASDAQ: BOWN) (“BOWN”). The Becker corporate team served as a U.S. legal advisor and included attorneys, Jie Chengying Xiu, Steven L. Glauberman and Priscilla Bonsu, of the firm’s New York office.
Qianzhi BioTech, based in Shenzhen, China, is a health and wellness-focused biotech company and an early adopter and developer of plant-based and ozonated products for antibacterial, skincare, gynecological, and andrological applications. Upon the closing of the Merger, the combined company is expected to remain a NASDAQ-listed public company trading under a new ticker symbol. The transaction was announced on January 18, 2024. It is expected to be consummated in the second or third quarter of 2024, subject to regulatory and stockholder approval by the stockholders of BOWN and NewCo and the satisfaction of certain other customary closing conditions.
Read the full press release here.
Becker’s Corporate Practice Group takes pride in being a valued part of our clients’ business team for corporate compliance and transactions, including, M&A, securities and corporate finance transactions, as well as legal issues relating to their operations. We make it a priority to understand our client’s operations and strategies and develop solutions from a business as well as a legal and regulatory perspective.
Becker, with headquarters in Fort Lauderdale, Fla., is a multi-practice commercial law firm with attorneys, lobbyists, and other professionals at offices throughout the East Coast. More information is available at www.beckerlawyers.com.